Captrust Financial Advisors Revance Therapeutics, Inc. Transaction History

Captrust Financial Advisors

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 16, 2022	BUY	$11.52 - $20.4 $4,423 - $7,833	384 Added 17.35%	2,597 $36,000
Q1 2022 May 16, 2022	SELL	$12.36 - $20.31 $5,549 - $9,119	-449 Reduced 16.87%	2,213 $43,000
Q4 2021 Feb 14, 2022	BUY	$12.46 - $27.87 $9,818 - $21,961	788 Added 42.05%	2,662 $43,000
Q2 2021 Aug 16, 2021	SELL	$26.8 - $31.84 $13,400 - $15,920	-500 Reduced 21.06%	1,874 $56,000
Q1 2021 May 17, 2021	BUY	$24.03 - $29.97 $15,186 - $18,941	632 Added 36.28%	2,374 $66,000
Q2 2020 Aug 14, 2020	BUY	$12.6 - $26.55 $21,949 - $46,250	1,742 New	1,742 $44,000
Q4 2019 Feb 14, 2020	SELL	$11.66 - $20.15 $2,332 - $4,029	-200 Closed	0 $0
Q3 2017 Feb 16, 2018	BUY	$22.55 - $28.1 $4,510 - $5,620	200	200 $6,000

234

82.8M

680K

896K

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

Stay updated on Captrust Financial Advisors with notifications on news.